104 related articles for article (PubMed ID: 16385077)
1. 3,3'-diindolylmethane is a novel topoisomerase IIalpha catalytic inhibitor that induces S-phase retardation and mitotic delay in human hepatoma HepG2 cells.
Gong Y; Firestone GL; Bjeldanes LF
Mol Pharmacol; 2006 Apr; 69(4):1320-7. PubMed ID: 16385077
[TBL] [Abstract][Full Text] [Related]
2. Daurinol, a catalytic inhibitor of topoisomerase IIα, suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phase.
Kang K; Nho CW; Kim ND; Song DG; Park YG; Kim M; Pan CH; Shin D; Oh SH; Oh HS
Int J Oncol; 2014 Aug; 45(2):558-66. PubMed ID: 24841075
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
[TBL] [Abstract][Full Text] [Related]
4. N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase.
Baviskar AT; Madaan C; Preet R; Mohapatra P; Jain V; Agarwal A; Guchhait SK; Kundu CN; Banerjee UC; Bharatam PV
J Med Chem; 2011 Jul; 54(14):5013-30. PubMed ID: 21644529
[TBL] [Abstract][Full Text] [Related]
5. HU-331 is a catalytic inhibitor of topoisomerase IIα.
Regal KM; Mercer SL; Deweese JE
Chem Res Toxicol; 2014 Dec; 27(12):2044-51. PubMed ID: 25409338
[TBL] [Abstract][Full Text] [Related]
6. The dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2α by enhancing pre-strand and post-strand cleavage and inhibiting DNA religation.
Zhao W; Jiang G; Bi C; Li Y; Liu J; Ye C; He H; Li L; Song D; Shao R
Oncotarget; 2015 Nov; 6(35):37871-94. PubMed ID: 26462155
[TBL] [Abstract][Full Text] [Related]
7. 3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage.
Park SE; Chang IH; Jun KY; Lee E; Lee ES; Na Y; Kwon Y
Eur J Med Chem; 2013 Nov; 69():139-45. PubMed ID: 24013413
[TBL] [Abstract][Full Text] [Related]
8. The p53 tumor suppressor stimulates the catalytic activity of human topoisomerase IIalpha by enhancing the rate of ATP hydrolysis.
Kwon Y; Shin BS; Chung IK
J Biol Chem; 2000 Jun; 275(24):18503-10. PubMed ID: 10764786
[TBL] [Abstract][Full Text] [Related]
9. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
10. β-Elemene Inhibits Cell Proliferation by Regulating the Expression and Activity of Topoisomerases I and IIα in Human Hepatocarcinoma HepG-2 Cells.
Gong M; Liu Y; Zhang J; Gao YJ; Zhai PP; Su X; Li X; Li Y; Hou L; Cui XN
Biomed Res Int; 2015; 2015():153987. PubMed ID: 26221582
[TBL] [Abstract][Full Text] [Related]
11. Selective killing of G2 decatenation checkpoint defective colon cancer cells by catalytic topoisomerase II inhibitor.
Jain CK; Roychoudhury S; Majumder HK
Biochim Biophys Acta; 2015 May; 1853(5):1195-204. PubMed ID: 25746763
[TBL] [Abstract][Full Text] [Related]
12. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of topoisomerase IIα sensitizes FaDu cells to ionizing radiation by diminishing DNA repair.
Saleh EM
Tumour Biol; 2015 Nov; 36(11):8985-92. PubMed ID: 26081617
[TBL] [Abstract][Full Text] [Related]
14. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
15. CS1 is a novel topoisomerase IIα inhibitor with favorable drug resistance profiles.
Shen Y; Chen W; Zhao B; Hao H; Li Z; Lu C; Shen Y
Biochem Biophys Res Commun; 2014 Oct; 453(3):302-8. PubMed ID: 25242524
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.
Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC
J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439
[TBL] [Abstract][Full Text] [Related]
17. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
18. Examination of the Impact of Copper(II) α-(N)-Heterocyclic Thiosemicarbazone Complexes on DNA Topoisomerase IIα.
Wilson JT; Jiang X; McGill BC; Lisic EC; Deweese JE
Chem Res Toxicol; 2016 Apr; 29(4):649-58. PubMed ID: 26982206
[TBL] [Abstract][Full Text] [Related]
19. Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha.
Bau JT; Kurz EU
Biochem Pharmacol; 2011 Feb; 81(3):345-54. PubMed ID: 20959117
[TBL] [Abstract][Full Text] [Related]
20. Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities.
Meyer KN; Kjeldsen E; Straub T; Knudsen BR; Hickson ID; Kikuchi A; Kreipe H; Boege F
J Cell Biol; 1997 Feb; 136(4):775-88. PubMed ID: 9049244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
